SRT for Oligoprogression in Metastatic RCC Patients Receiving TKI Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study
Eur Urol 2021 Aug 13;[EPub Ahead of Print], P Cheung, S Patel, SA North, A Sahgal, W Chu, H Soliman, B Ahmad, E Winquist, T Niazi, F Patenaude, G Lim, DYC Heng, A Dubey, P Czaykowski, RKS Wong, A Swaminath, SC Morgan, R Mangat, S Keshavarzi, GA BjarnasonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.